SCHEMBL11299370

SCHEMBL11299370

O=c1nccnc2ncccc12

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 4/20 0.42
MAPT P10636 1/20 0.42
PARP1 P09874 4/20 0.41
LMNA P02545 1/20 0.41
HCAR2 Q8TDS4 1/20 0.41
AURKA O14965 1/20 0.39
KMT2A Q03164 2/20 0.38
TDP2 O95551 1/20 0.38
NSD2 O96028 1/20 0.38
ABL1 P00519 1/20 0.38
PLCG1 P19174 1/20 0.38
CES1 P23141 1/20 0.38
PAX8 Q06710 1/20 0.38
RIN1 Q13671 1/20 0.38
MEN1 O00255 1/20 0.38
THRB P10828 1/20 0.38
BLM P54132 1/20 0.38
TDP1 Q9NUW8 1/20 0.38
GAA P10253 1/20 0.38
NPC1 O15118 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5239248 0.78 KDM4E (0.44) KDM4EMAPTPARP1LMNAHCAR2
SCHEMBL2877514 0.76 CYP3A4 (0.54) KDM4EMAPTPARP1LMNAAURKA
SCHEMBL2714092 0.76 MAPT (0.61) KDM4EMAPTPARP1LMNAKMT2A
SCHEMBL30183455 0.76 CYP3A4 (0.54) KDM4EMAPTPARP1LMNAAURKA
SCHEMBL2693525 0.73 HCAR2 (0.42) KDM4EMAPTLMNAHCAR2ALDH1A1
SCHEMBL8967704 0.73 CYP3A4 (0.46) KDM4EMAPTPARP1LMNAHCAR2
SCHEMBL277430 0.71 KDM4E (0.42) KDM4EMAPTPARP1LMNAHCAR2
SCHEMBL1014702 0.71 NCF1 (0.50) KDM4EMAPTPARP1NPC1ALDH1A1
SCHEMBL1907362 0.71 KDM4E (0.47) KDM4EMAPTLMNAKMT2ATDP2
SCHEMBL915425 0.70 F2 (0.43) KDM4EMAPTPARP1LMNAHCAR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260132127-A1 NOVEL SPIRO COMPOUND MITSUBISHI TANABE PHARMA CORPORATION (JP) 2026-05-14 US disclosed
EP-3700890-A1 NEW ALCOXYAMINO DERIVATIVES FOR TREATING PAIN AND PAIN RELATED CONDITIONS ESTEVE PHARMACEUTICALS, S.A. (ES) 2020-09-02 EP disclosed
WO-2012097479-A1 BICYCLIC INHIBITORS OF ANAPHASTIC LYMPHOMA KINASE ABBOTT LABORATORIES (US) 2012-07-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260132127-A1 NOVEL SPIRO COMPOUND TRHR, NR3C2, THRB KDM4E 4548/4885MAPT 4802/4885PARP1 4135/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.